1268 related articles for article (PubMed ID: 16782410)
1. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
Touyz RM; Schiffrin EL
Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
[TBL] [Abstract][Full Text] [Related]
2. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells.
Marx N; Duez H; Fruchart JC; Staels B
Circ Res; 2004 May; 94(9):1168-78. PubMed ID: 15142970
[TBL] [Abstract][Full Text] [Related]
3. Therapeutical effects of PPAR agonists assessed by biomarker modulation.
Chinetti-Gbaguidi G; Fruchart JC; Staels B
Biomarkers; 2005 Nov; 10 Suppl 1():S30-6. PubMed ID: 16298909
[TBL] [Abstract][Full Text] [Related]
4. PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia.
Hennuyer N; Tailleux A; Torpier G; Mezdour H; Fruchart JC; Staels B; Fiévet C
Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1897-902. PubMed ID: 15994444
[TBL] [Abstract][Full Text] [Related]
5. Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients.
Panunti B; Fonseca V
Vascul Pharmacol; 2006 Jul; 45(1):29-35. PubMed ID: 16777491
[TBL] [Abstract][Full Text] [Related]
6. [Peroxisome proliferator-activated receptors (PPAR) in pathophysiology of the circulatory system and prospective use of agonists of these receptors in therapy].
Bełtowski J; Wójcicka G; Jamroz A
Postepy Hig Med Dosw; 2003; 57(2):199-217. PubMed ID: 12866356
[TBL] [Abstract][Full Text] [Related]
7. Modulation of peroxisome proliferator-activated receptors (PPARs) by PPAR(alpha)- and PPAR(gamma)-specific ligands and by 17beta-estradiol in isolated zebrafish hepatocytes.
Ibabe A; Herrero A; Cajaraville MP
Toxicol In Vitro; 2005 Sep; 19(6):725-35. PubMed ID: 15964169
[TBL] [Abstract][Full Text] [Related]
8. Dual PPAR alpha/gamma agonists: promises and pitfalls in type 2 diabetes.
Ahmed I; Furlong K; Flood J; Treat VP; Goldstein BJ
Am J Ther; 2007; 14(1):49-62. PubMed ID: 17303976
[TBL] [Abstract][Full Text] [Related]
9. PPAR ligands: are they potential agents for cardiovascular disorders?
Balakumar P; Rose M; Singh M
Pharmacology; 2007; 80(1):1-10. PubMed ID: 17496434
[TBL] [Abstract][Full Text] [Related]
10. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors.
Michalik L; Auwerx J; Berger JP; Chatterjee VK; Glass CK; Gonzalez FJ; Grimaldi PA; Kadowaki T; Lazar MA; O'Rahilly S; Palmer CN; Plutzky J; Reddy JK; Spiegelman BM; Staels B; Wahli W
Pharmacol Rev; 2006 Dec; 58(4):726-41. PubMed ID: 17132851
[TBL] [Abstract][Full Text] [Related]
11. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists.
Libby P; Plutzky J
Am J Cardiol; 2007 Feb; 99(4A):27B-40B. PubMed ID: 17307056
[TBL] [Abstract][Full Text] [Related]
12. Peroxisome proliferator-activated receptors and acute lung injury.
Cuzzocrea S
Curr Opin Pharmacol; 2006 Jun; 6(3):263-70. PubMed ID: 16580256
[TBL] [Abstract][Full Text] [Related]
13. Can PPARgamma agonists have a role in the management of obesity-related hypertension?
Chetty VT; Sharma AM
Vascul Pharmacol; 2006 Jul; 45(1):46-53. PubMed ID: 16713364
[TBL] [Abstract][Full Text] [Related]
14. Peroxisome proliferator-activated receptor alpha and gamma ligands differentially affect smooth muscle cell proliferation and migration.
Zahradka P; Wright B; Fuerst M; Yurkova N; Molnar K; Taylor CG
J Pharmacol Exp Ther; 2006 May; 317(2):651-9. PubMed ID: 16407462
[TBL] [Abstract][Full Text] [Related]
15. Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases?
Becker J; Delayre-Orthez C; Frossard N; Pons F
Fundam Clin Pharmacol; 2006 Oct; 20(5):429-47. PubMed ID: 16968414
[TBL] [Abstract][Full Text] [Related]
16. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism.
Fogo AB
Curr Opin Nephrol Hypertens; 2008 May; 17(3):282-5. PubMed ID: 18408479
[TBL] [Abstract][Full Text] [Related]
17. Vascular effects of PPARgamma activators - from bench to bedside.
Marx N; Walcher D
Prog Lipid Res; 2007 Nov; 46(6):283-96. PubMed ID: 17637478
[TBL] [Abstract][Full Text] [Related]
18. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
Tjokroprawiro A
Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
[TBL] [Abstract][Full Text] [Related]
19. [Role of the peroxisome proliferator-activated receptors (PPARS) in the regulation of lipids and inflammation control].
Bocher V; Chinetti G; Fruchart JC; Staels B
J Soc Biol; 2002; 196(1):47-52. PubMed ID: 12134632
[TBL] [Abstract][Full Text] [Related]
20. Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism.
Gilde AJ; van der Lee KA; Willemsen PH; Chinetti G; van der Leij FR; van der Vusse GJ; Staels B; van Bilsen M
Circ Res; 2003 Mar; 92(5):518-24. PubMed ID: 12600885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]